PEOPLE - Nanyang Management makes appointment:
This article was originally published in Clinica
Mike Hirshorn, one of Australia's most experienced medical technology commercialisation executives, has joined venture capital firm Nanyang Management. Mr Hirshorn is one of the founders of cochlear implant company Cochlear. He was also a founding director of sleep apnoea Nasdaq-listed Australian company Resmed and until recently was with Polartechnics, which is commercialising a cervical screening and melanoma detection device. With the addition of Mr Hirshorn, Nanyang, which manages St George Development Capital Fund and focuses on technology and specialised manufacturing, will also take an interest in medical devices.
You may also be interested in...
The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.
Swissmedic says its good manufacturing practice certificates remain valid for longer than companies might assume. Separately, it is giving companies more time to conduct nitrosamine-related risk evaluations.
Stada has appointed a head of digital communications; PGEU elects new chair and vice-chair; and the new UK health claims committee unveils its first members.